Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0120

Next Previous
Drug Profile

AZD 0120

Alternative Names: AZD-0120; BCMA-Antigen X Bispecific CAR-Modified T Cells-Gracell-Biotechnology; BCMA-Antigen X bispecific CAR-T cells; BCMA/CD19 dual-target CAR-T cell immunotherapy - Gracell Biotechnology; BCMA/CD19 dual-targeting CAR-T therapy; CD19-BCMA CAR-T cells; Dual CAR-BCMA-19; FasTCAR-T GC012F; GC 012; GC-012F

Latest Information Update: 30 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gracell Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Systemic lupus erythematosus
  • Phase 0 Myasthenia gravis
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Jul 2025 Gracell Biotechnology plans a phase I trial for Idiopathic Inflammatory Myopathy (In adults, In the elderly) in September (IV) (NCT07086404)
  • 23 Jul 2025 Alexion Pharmaceuticals plans a phase I/II trial for Amyloid light chain amyloidosis (Treatment-experienced) (IV) in October 2025 (NCT07081646)
  • 18 Jul 2025 Gracell Biotechnology plans a phase-0 trial for Autoimmune disorders in August 2025 (IV, Injection), (NCT07072884)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top